Hepatitis C virus (HCV) infection can result in varied clinical outcomes including acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Chromic infections are common (>80% of these infected) and an estimated 170 million people are infected worldwide. Despite a great deal of progress, a vast number of unanswered questions remain concerning HCV replication, pathogenesis and immunity. One advance has been the construction of full-length HCV cDNA clones capable of producing infectious RNA transcripts, a technology which is essential not only for future studies on the molecular details of HCV replication but also for defining virus-host interactions that influence clinical outcome. Such RNAs are infectious after direct intrahepatic inoculation of chimpanzees, but attempts to demonstrate their replication in cell culture have met with limited success. In this proposal, microarray analysis will be used to define gene expression patterns in cells that are permissive for HCV replication. Liver resident human hepatocytes capable of supporting HCV replication in vivo will be compared to primary hepatocyte cultures, hepatoma lines, and hepatoma sublines that have been selected for their ability to support persistent replication of engineered HCV replicons. In a related study, the effect of HCV infection and/or protein expression on cellular gene expression will be assessed. Model systems will include cell lines and transgenic mice allowing tightly regulated expression of the entire HCV polyprotein or individual proteins, hepatoma sublines before and after transfection with functional HCV replicon, and infected versus uninfected hepatocytes from a SCID-Hu mouse mode, from chimpanzees, and form clinical material. This information will be used as a starting point for studying the impact of HCV on cellular responses to cytokines and other signals and regulating cell growth, apoptosis and host immune responses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
7U19AI040034-06
Application #
6496112
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-02-01
Project End
2001-07-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
White, Bethany; Madden, Annie; Hellard, Margaret et al. (2013) Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs. Drug Alcohol Rev 32:419-25
Yee, Russell M; Lehil, Mandeep S; Rongey, Catherine et al. (2013) Impaired lymphocyte reactivity measured by immune function testing in untransplanted patients with cirrhosis. Clin Vaccine Immunol 20:526-9
Page, Kimberly; Osburn, William; Evans, Jennifer et al. (2013) Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 56:405-13
Reyes-del Valle, Jorge; de la Fuente, Cynthia; Turner, Mallory A et al. (2012) Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 86:11558-66
Asher, Alice; Lum, Paula J; Page, Kimberly (2012) Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report. J Assoc Nurses AIDS Care 23:16-29
Dias, Paulo Telles; Hahn, Judith A; Delwart, Eric et al. (2011) Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 11:208
Bacchetti, Peter; Boylan, Ross; Astemborski, Jacquie et al. (2011) Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. PLoS One 6:e20104
Levy, Vivian; Evans, Jennifer L; Stein, Ellen S et al. (2010) Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine 28:5947-51
Diamond, Deborah L; Syder, Andrew J; Jacobs, Jon M et al. (2010) Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 6:e1000719
Maher, Lisa; White, Bethany; Hellard, Margaret et al. (2010) Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine 28:7273-8

Showing the most recent 10 out of 25 publications